Medicine and Dentistry
Percutaneous Coronary Intervention
100%
Percutaneous Aortic Valve Replacement
100%
Midodrine
50%
Vasa Vasorum
50%
Atherosclerosis
50%
End Stage Renal Disease
50%
Optical Coherence Tomography
50%
Hemodialysis
50%
Thrombus
50%
Contraindication
50%
Progenitor Cell
50%
Anticoagulation
50%
Anticoagulant Therapy
50%
Flexibility
50%
Public Health
50%
Macrophage
37%
Adventitia
37%
Endothelial Cell
25%
C57BL/6
25%
Angiography
23%
Apoplexy
23%
Atrial Fibrillation
18%
Brain Ischemia
16%
Ischemia
12%
Atherogenic Diet
12%
Atherogenesis
12%
Matrigel
12%
Hindlimb
12%
Microvessel
12%
Thromboembolism
9%
Relative Risk Reduction
9%
Bleeding
9%
Surgeon
7%
Radiation Exposure
6%
Intravascular Imaging
6%
Patient Care
6%
Medical Record
6%
Myocardial Infarction
6%
Sudden Death
6%
Chronic Disease
6%
Heart Death
6%
Coronary Artery Disease
6%
Clinical Trial Design
6%
Malignant Neoplasm
6%
All Cause Mortality
6%
Retrospective Study
6%
Congestive Heart Failure
6%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial Design
50%
Malignant Neoplasm
50%
Sudden Death
50%
Heart Infarction
50%
Coronary Artery Disease
50%
Heart Death
50%
Chronic Disease
50%
Anticoagulation Therapy
50%
Remission
50%
Tumor Necrosis Factor Inhibitor
50%
Psoriatic Arthritis
50%
Congestive Heart Failure
50%
Disease Activity
43%
Atrial Fibrillation
18%
Brain Ischemia
13%
Bleeding
9%
Thromboembolism
9%
Cerebrovascular Accident
9%
Golimumab
6%
Adalimumab
6%
Biological Product
6%
Etanercept
6%
Infliximab
6%
Comorbidity
6%
Nursing and Health Professions
Percutaneous Coronary Intervention
50%
Contraindication
50%
Anticoagulant Therapy
50%
Anticoagulation
50%
Remission
50%
Tumor Necrosis Factor Inhibitor
50%
Psoriatic Arthritis
50%
Health Assessment Questionnaire
25%
Clinical Disease Activity Index
25%
Disease Activity
18%
Atrial Fibrillation
18%
Brain Ischemia
13%
Bleeding
9%
Thromboembolism
9%
Cerebrovascular Accident
9%
Medical Record
6%
Heart Infarction
6%
Sudden Death
6%
Chronic Disease
6%
Malignant Neoplasm
6%
Heart Death
6%
Coronary Artery Disease
6%
Infliximab
6%
Etanercept
6%
Golimumab
6%
Patient Care
6%
Logistic Regression Analysis
6%
Body Mass
6%
Biological Product
6%
Adalimumab
6%
Visual Analog Scale
6%
Comorbidity
6%
Congestive Heart Failure
6%
